We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
-$31.8M
Cap. Flow %
-0.9%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
0.8 quarters
Top 20 Avg Time Held Equity + Options
1.2 quarters
Avg Time Held Equity only
4.3 quarters
Top 10 Avg Time Held Equity only
0.8 quarters
Top 20 Avg Time Held Equity only
1.2 quarters

Top Buys

Rank Stock Value
1
HCP icon
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN icon
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR icon
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO icon
Marathon Oil Corporation
MRO
+$123M
5
CHX icon
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD icon
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS icon
Discover Financial Services
DFS
+$45.1M
4
SCRM icon
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Miscellaneous 6.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRAX icon
226
Praxis Precision Medicines
PRAX
$7.26B
$1.48M 0.04%
35,729
+1,000
+3% +$47.3K
2022 Q1
9 quarters
SLN icon
227
Silence Therapeutics
SLN
$613M
$1.46M 0.04%
76,840
+4,617
+6% +$98.2K
2022 Q2
8 quarters
COHR icon
228
Coherent
COHR
$61.6B
$1.45M 0.04%
20,000
-17,069
-46% -$1.03M
2023 Q4
2 quarters
KALV icon
229
DELISTED
KalVista Pharmaceuticals
KALV
$1.45M 0.04%
122,960
+40,960
+50% +$478K
2024 Q1
1 quarter
WEL icon
230
DELISTED
Integrated Wellness Acquisition Corp
WEL
$1.45M 0.04%
125,054
– –
2022 Q1
9 quarters
RARE icon
231
Ultragenyx Pharmaceutical
RARE
$1.53B
$1.44M 0.04%
35,128
-7,478
-18% -$319K
2022 Q4
6 quarters
BAX icon
232
Baxter International
BAX
$12.6B
$1.44M 0.04%
43,126
-43,000
-50% -$1.58M
2023 Q4
2 quarters
SYRS icon
233
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.44M 0.04%
278,103
+103,103
+59% +$542K
2023 Q4
2 quarters
VERA icon
234
Vera Therapeutics
VERA
$2.15B
$1.43M 0.04%
39,416
+11,850
+43% +$470K
2023 Q1
5 quarters
TMCI icon
235
Treace Medical Concepts
TMCI
$257M
$1.42M 0.04%
212,976
+77,063
+57% +$623K
2022 Q1
9 quarters
BDTX icon
236
Black Diamond Therapeutics
BDTX
$105M
$1.42M 0.04%
303,706
+46,706
+18% +$251K
2024 Q1
1 quarter
LBPH icon
237
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.39M 0.04%
51,596
-2,457
-5% -$48.5K
2023 Q1
5 quarters
QCOM icon
238
Qualcomm
QCOM
$187B
$1.39M 0.04%
7,000
-8,500
-55% -$1.61M
2024 Q1
1 quarter
IAS icon
239
DELISTED
Integral Ad Science
IAS
$1.39M 0.04%
+142,500
New +$1.36M
2024 Q2
0 quarters
KIDS icon
240
OrthoPediatrics
KIDS
$565M
$1.38M 0.04%
48,097
-16,717
-26% -$512K
2022 Q1
9 quarters
IMCR icon
241
Immunocore
IMCR
$1.51B
$1.36M 0.04%
40,014
+11,090
+38% +$566K
2022 Q1
9 quarters
WMT icon
242
Walmart Inc
WMT
$883B
$1.35M 0.04%
+20,000
New +$1.26M
2024 Q2
0 quarters
NFYS icon
243
DELISTED
Enphys Acquisition Corp.
NFYS
$1.35M 0.04%
122,826
– –
2022 Q2
8 quarters
IQV icon
244
IQVIA
IQV
$42.8B
$1.34M 0.04%
+6,316
New +$1.43M
2024 Q2
0 quarters
MNSO icon
245
MINISO
MNSO
$2.81B
$1.33M 0.04%
+69,980
New +$1.54M
2024 Q2
0 quarters
ROIV icon
246
Roivant Sciences
ROIV
$25.6B
$1.31M 0.04%
124,217
+27,000
+28% +$296K
2022 Q4
6 quarters
MIRM icon
247
Mirum Pharmaceuticals
MIRM
$5.58B
$1.3M 0.04%
38,088
-11,769
-24% -$309K
2023 Q2
4 quarters
NKTR icon
248
Nektar Therapeutics
NKTR
$1.41B
$1.29M 0.04%
69,595
+7,220
+12% +$152K
2023 Q3
3 quarters
AGIO icon
249
Agios Pharmaceuticals
AGIO
$1.9B
$1.29M 0.04%
30,013
-49,893
-62% -$1.8M
2022 Q4
6 quarters
ESTA icon
250
Establishment Labs
ESTA
$1.84B
$1.29M 0.04%
28,445
-10,000
-26% -$507K
2022 Q1
9 quarters
8 9
10
11 12

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.